Cellectis (France) Today
| ALCLS Stock | EUR 1.93 0.06 3.21% |
Performance0 of 100
| Odds Of DistressLess than 39
|
Cellectis is selling at 1.93 as of the 30th of November 2024; that is 3.21 percent up since the beginning of the trading day. The stock's last reported lowest price was 1.87. Cellectis has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Cellectis are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. The company has 55.59 M outstanding shares. More on Cellectis
Moving against Cellectis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cellectis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cellectis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cellectis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Andre Choulika |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Cellectis (ALCLS) is traded on Euronext Paris in France and employs 294 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 118.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cellectis operates under Biotechnology sector and is part of Health Care industry. The entity has 55.59 M outstanding shares.
Cellectis has accumulated about 47.91 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cellectis Probability Of Bankruptcy
Ownership AllocationCellectis holds a total of 55.59 Million outstanding shares. Almost 78.75 percent of Cellectis outstanding shares are held by general public with 21.25 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cellectis Ownership Details
Cellectis Risk Profiles
Although Cellectis' alpha and beta are two of the key measurements used to evaluate Cellectis' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.56 | |||
| Standard Deviation | 2.14 | |||
| Variance | 4.56 | |||
| Risk Adjusted Performance | (0.03) |
Cellectis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cellectis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Cellectis Corporate Management
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Kyung NamWortman | Ex Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.